MetaCap

Amarin (AMRN) vs DiaMedica Therapeutics (DMAC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

DiaMedica Therapeutics (DMAC) has outperformed Amarin (AMRN) over the past year, gaining 8.1% versus a loss of 35.5%. Over five years, DMAC leads with a +118.8% price change compared with -85.5% for AMRN. DiaMedica Therapeutics is the larger company by market cap ($445.1 million vs $444.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRN-35.47%DMAC+8.13%
+45%+3%-39%
Nov 21, 20251 yearNov 20, 2026
AMRN-86.45%DMAC+115.97%
+158%+28%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRN versus DMAC key metrics
MetricAMRNDMAC
Share price$10.57$8.25
Market cap$444.39M$445.15M
1-day change-6.13%+2.87%
YTD return-24.28%+3.64%
1-year return-35.47%+8.13%
5-year return-85.48%+118.83%
Forward P/E10.79—
EPS (TTM)$-0.80$-0.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$213.65M—
Revenue growth (YoY)-6.55%—
Net income (latest FY)$-38.80M$-32.77M
Gross margin56.57%—
Operating margin-23.48%—
Net margin-18.16%—
52-week high$17.31$11.00
52-week low$10.56$5.25
Distance from 52-week high-38.94%-25.00%
Analyst consensusnonestrong_buy
Avg. price target upside+22.99%+96.97%
Average volume79.50K210.46K
Shares outstanding42.04M53.96M
Employees8035
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DMAC has outperformed AMRN by 43.6 percentage points over the past year.

About Amarin

AMRN stock →

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About DiaMedica Therapeutics

DMAC stock →

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.

Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees

AMRN vs DMAC FAQ

Which is bigger, Amarin or DiaMedica Therapeutics?

DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $445.15M compared with $444.39M for Amarin (AMRN).

Which stock has performed better over the past year, AMRN or DMAC?

DMAC returned +8.13% over the past 12 months, compared with -35.47% for AMRN (price return, excluding dividends). Past performance does not predict future results.

Are Amarin and DiaMedica Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons